Newly licensed drugs: Should be on probation until their value is demonstrated

British Medical Journal

Volumn 313, Issue 7066, 1996, Pages 1157-1158

  Ferner, R E ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENOXAPROFEN; BETA1 INTERFERON; GLATIRAMER; NEW DRUG; PRAVASTATIN;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; EDITORIAL; HUMAN; LICENCE; MULTIPLE SCLEROSIS; PRESCRIPTION; PRIORITY JOURNAL;

DRUG APPROVAL; GREAT BRITAIN; HUMANS; LEGISLATION, DRUG; LICENSURE; STATE MEDICINE;

EID: 0029841601     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a^tatistical reminder. BMJ 1995;311:619-20.
2. Rawlins MD. Pharmacovigilance: paradise lost, regained, or postponed? The VTilliam Withering Lecture 1994..?R Coll Physicians London 1995;29: 41-9.
3. Davey, PG, Bax RP, Newey J, Reeves D, Rutherford D, Slack R, et al Growth in the use of antibiotics in England and Scotland in 1980-93. BMJ 1996;312:613.
4. The IFXB multiple sclerosis study group. Interferon-beta-lb is effective in relapsing-remitting multiple sclerosis. l.Keiirology 1993;43:655-61.
5. Marson AG, Kadir ZA, Chadwick DW. New anriepileptic drugs: a systematic re\iew of their efficacy and tolerability. BMJ 1996;313:1169-740.
6. Walker MC, LJ LM, Sander J\X'AS. Long term use of lamotrigine and vigibamn in severe refractory epilepsy: audit of outcome. BMJ 1996;3I3:1184-5.
7. Mingot G. Drug trials in epilepsy. BMJ 1996;313:1158.
8. Peckham M, Smith R. Health care: what's science got to do with it? BMJ 1995;310:208.
9. Anonymous. Guidelines for the pharmaceutical industry on preparation of submissions involving economic analyses. Canberra: Commonwealth Department of Human Services and Health, 1995
10. Shepherd J, Cobbe S.M, Ford I, Isles CG, Lorimer AR, MacFarlane PW, ei al Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl jf Med 1995;333:1301-7.
11. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol in patients with and without pre-existing heart disease. BMjf 1996;312:1443-8.